The cholinergic system and Parkinson disease

Behavioural Brain Research

Volumn 221, Issue 2, 2011, Pages 564-573

  Bohnen, Nicolaas I ^a,b   Albin, Roger L ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Acetylcholine; Alzheimer disease; Cognition; Dementia with Lewy bodies; Dopamine; Motor; Olfaction; Parkinson disease; Parkinson disease with dementia; Positron emission tomography; Single photon emission tomography

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; RADIOLIGAND; VESICULAR ACETYLCHOLINE TRANSPORTER;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; BRAIN STEM; CEREBELLAR ATAXIA; CHOLINERGIC NERVE; CHOLINERGIC NERVE CELL; CHOLINERGIC SYNAPSE; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CORTICOBASAL DEGENERATION; DENERVATION; FOREBRAIN; HUMAN; HYPOSMIA; IN VIVO STUDY; MENTAL PERFORMANCE; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROPATHOLOGY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMELLING DISORDER; SYMPTOMATOLOGY; WORKING MEMORY;

BIOLOGICAL MARKERS; BRAIN STEM; CHOLINERGIC FIBERS; HUMANS; LEWY BODY DISEASE; MODELS, NEUROLOGICAL; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROSENCEPHALON;

EID: 79955746757     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.12.048     Document Type: Review

References (141)

1. Aarsland D., Kurz M.W. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2009, 10.1016/j.jns.2009.08.034.
2. Apicella P., Scarnati E., Schultz W. Tonically discharging neurons of monkey striatum respond to preparatory and rewarding stimuli. Exp Brain Res 1991, 84:672-675.
3. Arendt T., Bigl V., Arendt A., Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol (Berl) 1983, 61:101-108.
4. Asahina M., Suhara T., Shinotoh H., Inoue O., Suzuki K., Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 1998, 65:155-163.
5. Atack J.R., Perry E.K., Bonham J.R., Candy J.M., Perry R.H. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986, 47:263-277.
6. Aubert I., Araujo D., Cecyre D., Robitaille Y., Gauthier S., Quirion R. Comparative alterations of nico-tinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 1992, 58:529-541.
7. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J 1962, 87:802-807.
8. Bedard M.A., Lemay S., Gagnon J.F., Masson H., Paquet F. Induction of a transient dysexecutive syndrome in Parkinson's disease using a subclinical dose of scopolamine. Behav Neurol 1998, 11:187-195.
9. Bedard M.A., Pillon B., Dubois B., Duchesne N., Masson H., Agid Y. Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome. Brain Cogn 1999, 40:289-313.
10. Blazquez P.M., Fujii N., Kojima J., Graybiel A.M. A network representation of response probability in the striatum. Neuron 2002, 33:973-982.
11. Bohnen N.I., Kaufer D.I., Hendrickson R., Constantine G.M., Mathis C.A., Moore R.Y. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry 2007, 78:641-643.
12. Bohnen N.I., Kaufer D.I., Hendrickson R., Ivanco L.S., Lopresti B.J., Constantine G.M., et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006, 253:242-247.
13. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003, 60:1745-1748.
14. Bohnen N.I., Muller M.L., Koeppe R.A., Studenski S.A., Kilbourn M.A., Frey K.A., et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009, 73:1670-1676.
15. Bohnen N.I., Muller M.L.T.M., Koeppe R.A., Kilbourn M.A., Frey K.A., Albin R.L. Ratings of activities of daily living are associated with cortical cholinergic but not with the degree of nigrostriatal dopaminergic activity in Parkinson disease. J Nucl Med 2009, 50(Suppl 2):238P.
16. Bowen D.M., Smith C.B., White P., Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976, 99:459-496.
17. Braak H., Del Tredici K., Bratzke H., Hamm-Clement J., Sandmann-Keil D., Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002, 249(Suppl 3). III/1-5.
18. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
19. Candy J.M., Perry R.H., Perry E.K., Irving D., Blessed G., Fairbairn A.F., et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci 1983, 59:277-289.
20. Chung K.A., Lobb B.M., Nutt J.G., Horak F. Cholinergic augmentation in frequently fallings subjects with Parkinson's disease. Mov Disord 2009, 24(Suppl 1):S259.
21. Churchyard A., Lees A. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997, 49:1570-1576.
22. Clarke C.E. Medical management of Parkinson's disease. J Neurol Neurosurg Psychiatry 2002, 72(Suppl 1):I22-I27.
23. Conroy W.G., Vernallis A.B., Berg D.K. The alpha 5 gene product assembles with multiple acetylcholine receptor subunits to form distinctive receptor subtypes in brain. Neuron 1992, 9:679-691.
24. Cools R. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006, 30:1-23.
25. Cools R., Lewis S.J., Clark L., Barker R.A., Robbins T.W. l-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007, 32:180-189.
26. Cooper J.A., Sagar H.J., Doherty S.M., Jordan N., Tidswell P., Sullivan E.V. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 1992, 115:1701-1725.
27. Davies P., Maloney A. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, (II):1403.
28. Davis K., Mohs R., Marin D., Purohit D., Perl D., Lantz M., et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999, 281:1401-1406.
29. de Lacalle S., Hersh L., Saper C. Cholinergic innervation of the human cerebellum. J Comp Neurol 1993, 328:364-376.
30. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002, 51:145-155.
31. Doty R.L., Bromley S.M., Stern M.B. Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria. Neurodegeneration 1995, 4:93-97.
32. Doty R.L., Reyes P.F., Gregor T. Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Res Bull 1987, 18:597-600.
33. Dubois B., Danze F., Pillon B., Cusimano G., Lhermitte F., Agid Y. Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol 1987, 22:26-30.
34. Dubois B., Pillon B., Lhermitte F., Agid Y. Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol 1990, 28:117-121.
35. Duvoisin R.C. Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 1967, 17:124-136.
36. Edison P., Rowe C.C., Rinne J.O., Ng S., Ahmed I., Kemppainen N., et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008, 79:1331-1338.
37. Eglen R.M. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 2006, 26:219-233.
38. Fibiger H. The organization and some projections of cholinergic neurons of the mammalian forebrain. Brain Res Rev 1982, 4:327-388.
39. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 1992, 41:31-37.
40. Frey K., Ehrenkaufer R., Beaucage S., Agranoff B. Quantitative in vivo receptor binding I. Theory and application to the muscarinic cholinergic receptor. J Neurosci 1985, 5:421-428.
41. Fujita M., Ichise M., Zoghbi S.S., Liow J.S., Ghose S., Vines D.C., et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol 2006, 59:174-177.
42. Gai W.P., Halliday G.M., Blumbergs P.C., Geffen L.B., Blessing W.W. Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 1991, 114(Pt 5):2253-2267.
43. Geula C., Mesulam M.M. Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience 1989, 33:469-481.
44. Geula C., Mesulam M.M. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb Cortex 1996, 6:165-177.
45. Geula C., Mesulam M.M. Cholinergic systems in Alzheimer's disease. Alzheimer disease 1999, 69-292. Lippincott, Williams & Wilkins, Philadelphia, PA. 2nd ed. Terry RDea (Ed.).
46. Gibb W. Dementia and Parkinson's disease. Br J Psychiatry 1989, 154:596-614.
47. Gilman S., Chervin R.D., Koeppe R.A., Consens F.B., Little R., An H., et al. Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA. Neurology 2003, 61:35-39.
48. Gilman S., Koeppe R.A., Nan B., Wang C.N., Junck L., Chervin R.D., et al. Cerebral cholinergic deficits in Parkinsonian syndromes. Neurology 2009, 72(Suppl 3):A145-A146.
49. Goldman-Rakic P.S. The cortical dopamine system: role in memory and cognition. Adv Pharmacol 1998, 42:707-711.
50. Gotham A.M., Brown R.G., Marsden C.D. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988, 111:299-321.
51. Green J., McDonald W.M., Vitek J.L., Evatt M., Freeman A., Haber M., et al. Cognitive impairments in advanced PD without dementia. Neurology 2002, 59:1320-1324.
52. Haehner A., Boesveldt S., Berendse H.W., Mackay-Sim A., Fleischmann J., Silburn P.A., et al. Prevalence of smell loss in Parkinson's disease-a multicenter study. Parkinsonism Relat Disord 2009, 15:490-494.
53. Hawkes C.H., DelTredici K., Braak H. Parkinson's disease: the dual hit theory revisited. Ann NY Acad Sci 2009, 1170:615-622.
54. Hawkes C.H., Shephard B.C. Olfactory evoked responses and identification tests in neurological disease. Ann NY Acad Sci 1998, 855:608-615.
55. Heckers S., Geula C., Mesulam M. Cholinergic innervation of the human thalamus: dual origin and differential nuclear distribution. J Comp Neurol 1992, 325:68-82.
56. Heckers S., Geula C., Mesulam M.M. Acetylcholinesterase-rich pyramidal neurons in Alzheimer's disease. Neurobiol Aging 1992, 13:455-460.
57. Hilker R., Thomas A.V., Klein J.C., Weisenbach S., Kalbe E., Burghaus L., et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005, 65:1716-1722.
58. Hirano S., Shinotoh H., Arai K., Aotsuka A., Yasuno F., Tanaka N., et al. PET study of brain acetylcholinesterase in cerebellar degenerative disorders. Mov Disord 2008, 23:1154-1160.
59. Hirsch E.C., Graybiel A.M., Duyckaerts C., Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 1987, 84:5976-5980.
60. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987, 45:19-34.
61. Irie T., Fukushi K., Akimoto Y., Tamagami H., Nozaki T. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol 1994, 21.
62. Jellinger K. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1988, 51:540-543.
63. Kareken D.A., Mosnik D.M., Doty R.L., Dzemidzic M., Hutchins G.D. Functional anatomy of human odor sensation, discrimination, and identification in health and aging. Neuropsychology 2003, 17:482-495.
64. Kas A., Bottlaender M., Gallezot J.D., Vidailhet M., Villafane G., Gregoire M.C., et al. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J Cereb Blood Flow Metab 2009, 29:1601-1608.
65. Kilbourn M., Snyder S., Sherman P., Kuhl D. In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperdinyl-4-propionate ([11C]PMP). Synapse 1996, 22:123-131.
66. Kimura M. Behaviorally contingent property of movement-related activity of the primate putamen. J Neurophysiol 1990, 63:1277-1296.
67. Kobayashi R., Palkovits M., Hruska R., Rothschild R., Yamamura H. Regional distribution of muscarinic cholinergic receptors in rat brain. Brain Res 1978, 154:13-23.
68. Korczyn A.D. Dementia in Parkinson's disease. J Neurol 2001, 248(Suppl 3):III/1-III/4.
69. Kotagal V., Muller M.T., Koeppe R.A., Frey K.A., Albin R.L., Bohnen N.I. Parkinson and Alzheimer-selective hyposmia measures have different neurochemical substrates in patients with Parkinson's disease. Neurology 2009, 72(Suppl 3):A146.
70. Kuhl D., Minoshima S., Fessler J., Frey K., Foster N., Ficaro E., et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996, 40:399-410.
71. Kuhl D.E., Koeppe R.A., Fessler J.A., Minoshima S., Ackermann R.J., Carey J.E., et al. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med 1994, 35:405-410.
72. Lange K.W., Wells F.R., Jenner P., Marsden C.D. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J Neurochem 1993, 60:197-203.
73. Langston J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006, 59:591-596.
74. Lecourtier L., Kelly P.H. A conductor hidden in the orchestra? Role of the habenular complex in monoamine transmission and cognition. Neurosci Biobehav Rev 2007, 31:658-672.
75. Lee M.S., Rinne J.O., Marsden C.D. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 2000, 41:167-184.
76. Lehericy S., Hirsch E.C., Cervera-Pierot P., Hersh L.B., Bakchine S., Piette F., et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol 1993, 330:15-31.
77. Lewy F.H. Zur pathologischen Anatomie der Paralysis agitans. Dtsch Ztschr Nervenheilkunde 1913, 50:50-55.
78. Lieberman A. Are dementia and depression in Parkinson's disease related?. J Neurol Sci 2006, 248:138-142.
79. Lieberman A., Dziatolowski M., Kupersmith M., Serby M., Goodgold A., Korein J., et al. Dementia in Parkinson's disease. Ann Neurol 1979, 6:355-359.
80. Mahler M.E., Cummings J.L. Alzheimer disease and the dementia of Parkinson disease: Comparative investigations. Alzheimer Dis Assoc Disord 1990, 4:133-149.
81. Marder K., Tang M.-X., Côté L., Stern Y., Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995, 52:695-701.
82. Mash D.C., White W.F., Mesulam M.M. Distribution of muscarinic receptor subtypes within architectonic subregions of the primate cerebral cortex. J Comp Neurol 1988, 278:265-274.
83. Mattila P.M., Roytta M., Lonnberg P., Marjamaki P., Helenius H., Rinne J.O. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol (Berl) 2001, 102:160-166.
84. Mattila P.M., Roytta M., Torikka H., Dickson D.W., Rinne J.O. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol (Berl) 1998, 95:576-582.
85. Mayeux R., Stern Y., Rosen J., Leventhal J. Depression, intellectual impairment, and Parkinson's disease. Neurology 1981, 31:645-650.
86. Mayeux R., Stern Y., Rosenstein R., Marder K., Hauser A., Côté L., et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988, 45:260-262.
87. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
88. Mesholam R.I., Moberg P.J., Mahr R.N., Doty R.L. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol 1998, 55:84-90.
89. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. Learn Mem 2004, 11:43-49.
90. Mesulam M., Mash D., Hersh L., Bothwell M., Geula C. Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. J Comp Neurol 1992, 323:252-268.
91. Mesulam M.M., Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988, 275:216-240.
92. Mesulam M.M., Geula C. Overlap between acetylcholinesterase-rich and choline acetyltransferase-positive (cholinergic) axons in human cerebral cortex. Brain Res 1992, 577:112-120.
93. Meyer P.M., Strecker K., Kendziorra K., Becker G., Hesse S., Woelpl D., et al. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009, 66:866-877.
94. Mufson E.J., Ma S.Y., Dills J., Cochran E.J., Leurgans S., Wuu J., et al. Loss of basal forebrain P75 (NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 2002, 443:136-153.
95. Muller A., Mungersdorf M., Reichmann H., Strehle G., Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002, 9:521-524.
96. Murphy C., Gilmore M.M., Seery C.S., Salmon D.P., Lasker B.R. Olfactory thresholds are associated with degree of dementia in Alzheimer's disease. Neurobiol Aging 1990, 11:465-469.
97. Nakano I., Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984, 5:415-418.
98. Namba H., Shinotoh H., Iyo M. In vivo measurement of acetylcholinesterase activity of the brains of Alzheimer's disease and Parkinson's disease. J Nucl Med 1998, 39(Suppl):95P-96P.
99. Pahapill P.A., Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 2000, 123:1767-1783.
100. Papp M.I., Lantos P.L. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994, 117:235-243.
101. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000, 61:75-111.
102. Perry E.K., Curtis M., Dick D.J., Candy J.M., Atack J.R., Bloxham C.A., et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985, 48:413-421.
103. Perry E.K., Irving D., Kerwin J.M., McKeith I.G., Thompson P., Collerton D., et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993, 7:69-79.
104. Perry E.K., Perry R.H. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995, 28:240-258.
105. Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977, 189.
106. Pimlott S.L., Piggott M., Owens J., Greally E., Court J.A., Jaros E., et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 2004, 29:108-116.
107. Pirozzolo F.J., Hansch E.C., Mortimer J.A., Webster D.D., Kuskowski M.A. Dementia in Parkinson disease: a neuropsychological analysis. Brain Cogn 1982, 1:71-83.
108. Pisani A., Bernardi G., Ding J., Surmeier D.J. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 2007, 30:545-553.
109. Potagas C., Dellatolas G., Ziegler M., Leveteau J., Bathien N., Mac Leod P., et al. Clinical assessment of olfactory dysfunction in Parkinson's disease. Mov Disord 1998, 13:394-399.
110. Raz A., Feingold A., Zelanskaya V., Vaadia E., Bergman H. Neuronal synchronization of tonically active neurons in the striatum of normal and parkinsonian primates. J Neurophysiol 1996, 76:2083-2088.
111. Rogers J.D., Brogan D., Mirra S.S. The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol 1985, 17:163-170.
112. Ruberg M., Ploska A., Javoy-Agid F., Agid Y. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res 1982, 232:129-139.
113. Ruberg M., Rieger F., Villageois A., Bonnet A.M., Agid Y. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res 1986, 362:83-91.
114. Samuel W., Alford M., Hofstetter C.R., Hansen L. Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997, 56:499-508.
115. Selden N.R., Gitelman D.R., Salamon-Murayama N., Parrish T.B., Mesulam M.M. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998, 121:2249-2257.
116. Serby M., Larson P., Kalkstein D. The nature and course of olfactory deficits in Alzheimer's disease. Am J Psychiatry 1991, 148:357-360.
117. Shimada H., Hirano S., Shinotoh H., Aotsuka A., Sato K., Tanaka N., et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009, 73:273-278.
118. Shinotoh H. Neuroimaging of PD, PSP, CBD and MSA-PET and SPECT studies. J Neurol 2006, 253(Suppl 3):iii30-iii34.
119. Shinotoh H., Namba H., Yamaguchi M., Fukushi K., Nagatsuka S., Iyo M., et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 1999, 46:62-69.
120. Shute C.C., Lewis P.R. Electron microscopy of cholinergic terminals and acetylcholinesterase-containing neurones in the hippocampal formation of the rat. Z Zellforsch Mikrosk Anat 1966, 69:334-343.
121. Silveira-Moriyama L., Holton J.L., Kingsbury A., Ayling H., Petrie A., Sterlacci W., et al. Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci Lett 2009, 453:77-80.
122. Steele J.C., Richardson J.C., Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brainstem, basal ganglia, and cerebellum, with vertical gaze and pseudobulbar palsy. Arch Neurol 1964, 10:333-359.
123. Stein J.F. Akinesia, motor oscillations and the pedunculopontine nucleus in rats and men. Exp Neurol 2009, 215:1-4.
124. Suzuki M., Desmond T.J., Albin R.L., Frey K.A. Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology 2002, 58:1013-1018.
125. Tabert M.H., Liu X., Doty R.L., Serby M., Zamora D., Pelton G.H., et al. A 10-item smell identification scale related to risk for Alzheimer's disease. Ann Neurol 2005, 58:155-160.
126. Tagliavini F., Pilleri G., Bouras C., Constantinidis J. The basal nucleus of Meynert in idiopathic Parkinson's disease. Acta Neurol Scand 1984, 70:20-28.
127. Taylor J.P., Rowan E.N., Lett D., O'Brien J.T., McKeith I.G., Burn D.J. Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype. J Neurol Neurosurg Psychiatry 2008, 79:1318-1323.
128. Tiraboschi P., Hansen L.A., Alford M., Masliah E., Thal L.J., Corey-Bloom J. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology 2000, 55:1278-1283.
129. Tiraboschi P., Hansen L.A., Alford M., Merdes A., Masliah E., Thal L.J., et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002, 59:946-951.
130. Tiraboschi P., Hansen L.A., Alford M., Sabbagh M.N., Schoos B., Masliah E., et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000, 54:407-411.
131. Tröster A.I., Stalp L.D., Paolo A.M., Fields J.A., Koller W.C. Neuropsychological impairment in Parkinson's disease with and without depression. Arch Neurol 1995, 52:1164-1169.
132. Weihe E., Tao-Cheng J.H., Schafer M.K., Erickson J.D., Eiden L.E. Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. Proc Natl Acad Sci USA 1996, 93:3547-3552.
133. Weintraub D., Morales K.H., Moberg P.J., Bilker W.B., Balderston C., Duda J.E., et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005, 20:1161-1169.
134. Whitehouse P.J., Hedreen J.C., White C.L., Price D.L. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983, 13:243-248.
135. Whitehouse P.J., Martino A.M., Wagster M.V., Price D.L., Mayeux R., Atack J.R., et al. Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology 1988, 38:720-723.
136. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981, 10:122-126.
137. Williams-Gray C.H., Evans J.R., Goris A., Foltynie T., Ban M., Robbins T.W., et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009, 132:2958-2969.
138. Wilson R.S., Arnold S.E., Schneider J.A., Tang Y., Bennett D.A. The relationship between cerebral Alzheimer's disease pathology and odour identification in old age. J Neurol Neurosurg Psychiatry 2007, 78:30-35.
139. Yan Z., Feng J. Alzheimer's disease: interactions between cholinergic functions and beta-amyloid. Curr Alzheimer Res 2004, 1:241-248.
140. Zaccai J., McCracken C., Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005, 34:561-566.
141. Zweig R.M., Jankel W.R., Hedreen J.C., Mayeux R., Price D.L. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 1989, 26:41-46.